Skip to main content
SpringerLink
Log in

Klinische, pathologische und molekulare Biomarker der Hidradenitis suppurativa/Acne inversa

Clinical, pathology-associated and molecular biomarkers of hidradenitis suppurativa/acne inversa

  • Leitthema
  • Published:
Der Hautarzt Aims and scope Submit manuscript

An Erratum to this article was published on 23 August 2021

This article has been updated

Zusammenfassung

Die Hidradenitis suppurativa/Acne inversa ist eine vernarbende Erkrankung der Intertrigines, die heute intensiv beforscht wird. Durch das verbesserte pathogenetische Verständnis kam es zur Einführung der Tumornekrosefaktor(TNF)-α-Hemmung, was einen großen Fortschritt gegenüber der traditionellen breiten Immunsuppression und Antibiotikagabe darstellt. Aber auch ein breites Spektrum von neueren und vielversprechenden Behandlungszielen ist oder steht vor der klinischen Evaluation. Dazu gehören verschiedene spezifische Antikörper gegen Zytokine und das Komplementsystem und kleine Moleküle. Ein erfolgreicher Einsatz der einzelnen Medikamente hängt von der Stratifizierung der geeigneten Patientengruppen nach klinisch relevanten Biomarkern ab. Während Molekularuntersuchungen eine Reihe von möglichen Biomarkern bzw. therapeutischen Zielmolekülen nachgewiesen haben, befindet sich der Nachweis robuster prädiktiver Biomarker noch in seiner Anfangsphase. Zusammenfassend werden die Therapieoptionen der Hidradenitis suppurativa/Acne inversa durch die Einführung neuer Medikamente ggf. in Kombination mit chirurgischen Eingriffen stets besser, wobei die Möglichkeiten zur prädiktiven Therapieentscheidung durch die Entdeckung von Biomarkern die therapeutischen Erfolgschancen revolutionieren können.

Abstract

Hidradenitis suppurativa/acne inversa is a scarring disease of the intertrigines that is now intensively researched. Improved pathogenetic understanding has led to the introduction of tumor necrosis factor alpha (TNF‑α) inhibition, which represents a major advance over traditional broad immunosuppression and antibiotic administration. In addition, a wide range of newer and promising treatments is or is about to be clinically evaluated. These include various specific antibodies against cytokines and the complement system and small molecules. Successful use of the individual drugs depends on the stratification of suitable patient groups with the help of clinically relevant biomarkers. While molecular investigations have shown a number of possible biomarkers and/or therapeutic target molecules, the detection of robust predictive biomarkers is still in its initial phase. In summary, the therapeutic options for hidradenitis suppurativa/acne inversa are improving through the introduction of new drugs, possibly in combination with surgical interventions, whereby the possibilities for predictive therapeutic decisions through the discovery of biomarkers would revolutionize the chances of therapeutic success.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5

Change history

Literatur

  1. Alwan W, Nestle FO (2015) Pathogenesis and treatment of psoriasis: exploiting pathophysiological pathways for precision medicine. Clin Exp Rheumatol 33(suppl 93):S2–S6

    PubMed  Google Scholar 

  2. Balabanova S, Buhler G, Schneider E, Boschek HJ, Schneitler H (1992) Über die Ausscheidung von Nikotin mit dem apokrinen und ekkrinen Schweiß bei Rauchern und Passivrauchern. Hautarzt 43:73–76

    CAS  PubMed  Google Scholar 

  3. Blok JL, Li K, Brodmerkel C, Jonkman MF, Horváth B (2016) Gene expression profiling of skin and blood in hidradenitis suppurativa. Br J Dermatol 174:1392–1394

    Article  CAS  PubMed  Google Scholar 

  4. Boer J, Weltevreden EF (1996) Hidradenitis suppurativa or acne inversa. A clinicopathological study of early lesions. Br J Dermatol 135:721–725

    Article  CAS  PubMed  Google Scholar 

  5. Byrd AS, Dina Y, Okoh UJ et al (2019) Specimen collection for translational studies in hidradenitis suppurativa. Sci Rep 9:12207

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Caposiena Caro RD, Chiricozzi A, Sechi A et al (2021) Factors related to the onset and recurrence of flares in hidradenitis suppurativa patients treated with adalimumab. Ital J Dermatol Venerol. https://doi.org/10.23736/S2784-8671.21.06966-8

    Article  PubMed  Google Scholar 

  7. Coates M, Mariottoni P, Corcoran DL et al (2019) The skin transcriptome in hidradenitis suppurativa uncovers an antimicrobial and sweat gland gene signature which has distinct overlap with wounded skin. PLoS ONE 14:e216249

    Article  PubMed  PubMed Central  Google Scholar 

  8. Danby FW, Jemec GB, Marsch WC, von Laffert M (2013) Preliminary findings suggest hidradenitis suppurativa may be due to defective follicular support. Br J Dermatol 168:1034–1039

    Article  CAS  PubMed  Google Scholar 

  9. De Vita V, McGonagle D (2018) Hidradenitis suppurativa as an autoinflammatory keratinization disease. J Allergy Clin Immunol 141:1953

    Article  PubMed  Google Scholar 

  10. Di Caprio R, Balato A, Caiazzo G et al (2017) IL-36 cytokines are increased in acne and hidradenitis suppurativa. Arch Dermatol Res 309:673–678

    Article  PubMed  CAS  Google Scholar 

  11. Dunstan RW, Salte KM, Todorović V et al (2020) Histologic progression of acne inversa/hidradenitis suppurativa: implications for future investigations and therapeutic intervention. Exp Dermatol 30:820–830

    Article  CAS  Google Scholar 

  12. Emelianov VU, Bechara FG, Glaser R et al (2012) Immunohistological pointers to a possible role for excessive cathelicidin (LL-37) expression by apocrine sweat glands in the pathogenesis of hidradenitis suppurativa/acne inversa. Br J Dermatol 166:1023–1034

    Article  CAS  PubMed  Google Scholar 

  13. Fismen S, Ingvarsson G, Moseng D, Dufour DN, Jørgensen L (2012) A clinical-pathological review of hidradenitis suppurativa: using immunohistochemistry one disease becomes two. Apmis 120:433–440

    Article  PubMed  Google Scholar 

  14. Frew JM, Hawkes JE, Sullivan-Whalen M, Gilleaudeau P, Krueger JG (2019) Inter-rater reliability of phenotypes and exploratory genotype-phenotype analysis in inherited hidradenitis suppurativa. Br J Dermatol 181:566–571

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Fritsche E, Schäfer C, Calles C et al (2007) Lightening up the UV response by identification of the arylhydrocarbon receptor as a cytoplasmatic target for ultraviolet B radiation. Proc Natl Acad Sci U S A 104:8851–8856

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Giamarellos-Bourboulis EJ, Platzer M, Karagiannidis I et al (2016) High copy numbers of beta-defensin cluster on 8p23.1 confer genetic susceptibility and modulate the physical course of hidradenitis suppurativa/acne inversa. J Invest Dermatol 136:1592–1598

    Article  CAS  PubMed  Google Scholar 

  17. Gniadecki R, Jemec GB (2004) Lipid raft-enriched stem cell-like keratinocytes in the epidermis, hair follicles and sinus tracts in hidradenitis suppurativa. Exp Dermatol 13:361–363

    Article  PubMed  Google Scholar 

  18. Goertz RS, Konturek PC, Naegel A et al (2009) Experiences with a long-term treatment of a massive gluteal acne inversa with infliximab in Crohn’s disease. Med Sci Monit 15:CS14–CS18

    CAS  PubMed  Google Scholar 

  19. Grand D, Navrazhina K, Frew JW (2020) Integrating complement into the molecular pathogenesis of hidradenitis suppurativa. Exp Dermatol 29:86–92

    Article  PubMed  Google Scholar 

  20. Hana A, Booken D, Henrich C et al (2007) Functional significance of non-neuronal acetylcholine in skin epithelia. Life Sci 80:2214–2220

    Article  CAS  PubMed  Google Scholar 

  21. Hoffman LK, Tomalin LE, Schultz G et al (2018) Integrating the skin and blood transcriptomes and serum proteome in hidradenitis suppurativa reveals complement dysregulation and a plasma cell signature. PLoS ONE 13:e203672

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  22. Hofmann-Apitius M, Alarcón-Riquelme ME, Chamberlain C, McHale D (2015) Towards the taxonomy of human disease. Nat Rev Drug Discov 14:75–76

    Article  CAS  PubMed  Google Scholar 

  23. Hotz C, Boniotto M, Guguin A et al (2016) Intrinsic defect in keratinocyte function leads to inflammation in hidradenitis suppurativa. J Invest Dermatol 136:1768–1780

    Article  CAS  PubMed  Google Scholar 

  24. https://clinicaltrials.gov/ct2/results?recrs=&cond=Hidradenitis+Suppurativa&term=&cntry=&state=&city=&dist=. Zugegriffen: 4. März 2021

  25. Hunger RE, Surovy AM, Hassan AS, Braathen LR, Yawalkar N (2008) Toll-like receptor 2 is highly expressed in lesions of acne inversa and colocalizes with C‑type lectin receptor. Br J Dermatol 158:691–697

    Article  CAS  PubMed  Google Scholar 

  26. Iannone M, Janowska A, Bartolomei G et al (2021) Systemic antibiotics in hidradenitis suppurativa: efficacy and effects of body mass index and smoking pack-year on the response to therapy. Dermatol Ther 34:e14919

    Article  PubMed  Google Scholar 

  27. Jemec G, Hansen U (1996) Histology of hidradenitis suppurativa. J Am Acad Dermatol 34:994–999

    Article  CAS  PubMed  Google Scholar 

  28. Jemec GB (2003) Hidradenitis suppurativa. J Cutan Med Surg 7:47–56

    Article  PubMed  Google Scholar 

  29. Jenei A, Dajnoki Z, Medgyesi B et al (2019) Apocrine gland-rich skin has a non-inflammatory IL-17 related immune milieu, which turns to inflammatory IL-17 mediated disease in hidradenitis suppurativa. J Invest Dermatol 139:964–968

    Article  CAS  PubMed  Google Scholar 

  30. Jimenez-Gallo D, de la Varga-Martinez R, Ossorio-Garcia L, Albarran-Planelles C, Rodriguez C, Linares-Barrios M (2017) The clinical significance of increased serum proinflammatory cytokines, c‑reactive protein, and erythrocyte sedimentation rate in patients with hidradenitis suppurativa. Mediators Inflamm 2017:2450401

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Jimenez-Gallo D, de la Varga-Martinez R, Ossorio-Garcia L, Collantes-Rodriguez C, Rodriguez C, Linares-Barrios M (2018) Effects of adalimumab on T‑helper-17 lymphocyte- and neutrophil-related inflammatory serum markers in patients with moderate-to-severe hidradenitis suppurativa. Cytokine 103:20–24

    Article  CAS  PubMed  Google Scholar 

  32. Ju Q, Yu Q, Song N, Tan Y, Xia L, Zouboulis CC (2011) Expression of aryl hydrocarbon receptor in human epidermis, hair follicles and sebaceous glands and its significance. Chin J Dermatol 44:761–764

    CAS  Google Scholar 

  33. Kamp S, Fiehn AM, Stenderup K et al (2011) Hidradenitis suppurativa: a disease of the absent sebaceous gland? Sebaceous gland number and volume are significantly reduced in uninvolved hair follicles from patients with hidradenitis suppurativa. Br J Dermatol 164:1017–1022

    Article  CAS  PubMed  Google Scholar 

  34. Kanitakis J (2002) Anatomy, histology and immunohistochemistry of normal human skin. Eur J Dermatol 12:390–401

    PubMed  Google Scholar 

  35. Kanni T, Tzanetakou V, Savva A et al (2015) Compartmentalized cytokine responses in hidradenitis suppurativa. PLoS ONE 10:e130522

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  36. Kimball AB, Kerdel F, Adams D et al (2012) Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med 157:846–855

    Article  PubMed  Google Scholar 

  37. Kurokawa I, Nishijima S, Kusumoto K, Senzaki H, Shikata N, Tsubura A (2002) Immunohistochemical study of cytokeratins in hidradenitis suppurativa (acne inversa). J Int Med Res 30:131–136

    Article  CAS  PubMed  Google Scholar 

  38. Kurzen H, Jung EG, Hartschuh W et al (1999) Forms of epithelial differentiation of draining sinus in acne inversa (hidradenitis suppurativa). Br J Dermatol 41:231–239

    Article  Google Scholar 

  39. Kurzen H, Kurokawa I, Jemec GB (2008) What causes hidradenitis suppurativa? Exp Dermatol 17:457–472

    Article  Google Scholar 

  40. Lantuejoul S, Sound-Tsao M, Cooper WA et al (2020) PD-L1 Testing for lung cancer in 2019: Perspective from the IASLC pathology committee. J Thorac Oncol 15:499–519

    Article  CAS  PubMed  Google Scholar 

  41. Melnik BC, Plewig G (2013) Impaired Notch-MKP‑1 signalling in hidradenitis suppurativa: an approach to pathogenesis by evidence from translational biology. Exp Dermatol 22:172–177

    Article  CAS  PubMed  Google Scholar 

  42. Nicolas M, Wolfer A, Raj K et al (2003) Notch1 functions as a tumor suppressor in mouse skin. Nat Genet 33:416–421

    Article  CAS  PubMed  Google Scholar 

  43. Noakes R (2015) The aryl hydrocarbon receptor: a review of its role in the physiology and pathology of the integument and its relationship to the tryptophan metabolism. Int J Tryptophan Res 8:7–18

    Article  PubMed  PubMed Central  Google Scholar 

  44. Özkur E, Karadağ AS, Üstüner P et al (2021) Clinical and demographic features of hidradenitis suppurativa: a multicentre study of 1221 patients with an analysis of risk factors associated with disease severity. Clin Exp Dermatol 46:532–540

    Article  PubMed  Google Scholar 

  45. Pan Y, Lin MH, Tian X et al (2004) Gamma-secretase functions through Notch signaling to maintain skin appendages but is not required for their patterning or initial morphogenesis. Dev Cell 7:731–743

    Article  CAS  PubMed  Google Scholar 

  46. Plewig G, Steger M (1989) Acne inversa (alias acne triad, acne tetrad or hidradenitis suppurativa). In: Marks R, Plewig G (Hrsg) Acne and related disorders. Martin Dunitz, London, S 345–357

    Google Scholar 

  47. Schlapbach C, Hanni T, Yawalkar N, Hunger RE (2011) Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol 65:790–798

    Article  CAS  PubMed  Google Scholar 

  48. Schlapbach C, Yawalkar N, Hunger RE (2009) Human beta-defensin‑2 and psoriasin are overexpressed in lesions of acne inversa. J Am Acad Dermatol 61:58–65

    Article  CAS  PubMed  Google Scholar 

  49. Schrader AMR, Deckers IE, van der Zee HH, Boer J, Prens EP (2014) Hidradenitis suppurativa: a retrospective study of 846 Dutch patients to identify factors associated with disease severity. J Am Acad Dermatol 71:460–467

    Article  PubMed  Google Scholar 

  50. Shanmugam VK, Jones D, McNish S, Bendall ML, Crandall KA (2019) Transcriptome patterns in hidradenitis suppurativa: support for the role of antimicrobial peptides and interferon pathways in disease pathogenesis. Clin Exp Dermatol 44:882–892

    Article  CAS  PubMed  Google Scholar 

  51. Thomi R, Kakeda M, Yawalkar N, Schlapbach C, Hunger RE (2017) Increased expression of the interleukin-36 cytokines in lesions of hidradenitis suppurativa. J Eur Acad Dermatol Venereol 31:2091–2096

    Article  CAS  PubMed  Google Scholar 

  52. Thomi R, Schlapbach C, Yawalkar N, Simon D, Yerly D, Hunger RE (2018) Elevated levels of the antimicrobial peptide LL-37 in hidradenitis suppurativa are associated with a Th1/Th17 immune response. Exp Dermatol 27:172–177

    Article  CAS  PubMed  Google Scholar 

  53. Thomi R, Yerly D, Yawalkar N, Simon D, Schlapbach C, Hunger RE (2017) Interleukin-32 is highly expressed in lesions of hidradenitis suppurativa. Br J Dermatol 177:1358–1366

    Article  CAS  PubMed  Google Scholar 

  54. Tricarico P, Boniotto M, Genovese G, Zouboulis CC, Marzano AV, Crovella S (2019) Skin-OMICS: an integrated approach to unravel hidradenitis suppurativa etiopathogenesis. Front Immunol 10:892

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. van der Zee HH, de Ruiter L, van den Broecke DG, Dik WA, Laman JD, Prens EP (2011) Elevated levels of tumour necrosis factor (TNF)-alpha, interleukin (IL)-1beta and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-alpha and IL-1beta. Br J Dermatol 164:1292–1298

    Article  PubMed  CAS  Google Scholar 

  56. van der Zee HH, Laman JD, Boer J, Prens EP (2012) Hidradenitis suppurativa: viewpoint on clinical phenotyping, pathogenesis and novel treatments. Exp Dermatol 21:735–739

    Article  PubMed  CAS  Google Scholar 

  57. Verneuil A (1864) De l’hidrosadénite phlegmoneuse et des abscès sudoripares. Arch Gen Med 2:537–557

    Google Scholar 

  58. von Laffert M, Helmbold P, Wohlrab J, Fiedler E, Stadie V, Marsch WC (2010) Hidradenitis suppurativa (acne inversa): early inflammatory events at terminal follicles and at interfollicular epidermis. Exp Dermatol 19:533–537

    Article  Google Scholar 

  59. von Laffert M, Stadie V, Wohlrab J, Marsch WC (2011) Hidradenitis suppurativa/acne inversa: bilocated epithelial hyperplasia with very different sequelae. Br J Dermatol 164:367–371

    Article  Google Scholar 

  60. Vossen ARJV, Ardon CB, van der Zee HH, Lubberts E, Prens EP (2019) The anti-inflammatory potency of biologics targeting tumour necrosis factor‑a, interleukin (IL)-17A, IL-12/23 and CD20 in hidradenitis suppurativa: an ex vivo study. Br J Dermatol 181:314–323

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Wang B, Yang W, Wen W et al (2010) Gamma-secretase gene mutations in familial acne inversa. Science 330(6007):1065

    Article  CAS  PubMed  Google Scholar 

  62. Wolk K, Warszawska K, Hoeflich C et al (2011) Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa. J Immunol 186:1228–1239

    Article  CAS  PubMed  Google Scholar 

  63. Yen CF, Huang YH, Chi CC (2021) Concomitant psoriasis and hidradenitis suppurativa responsive to adalimumab therapy: a case series. Indian J Dermatol Venereol Leprol 87:223–226

    Article  PubMed  Google Scholar 

  64. Yu CC, Cook MG (1990) Hidradenitis suppurativa: a disease of follicular epithelium, rather than apocrine glands. Br J Dermatol 122:763–769

    Article  CAS  PubMed  Google Scholar 

  65. Zouboulis CC (2019) Ex vivo human models of hidradenitis suppurativa / acne inversa for laboratory research and drug screening. Br J Dermatol 181:244–246

    Article  CAS  PubMed  Google Scholar 

  66. Zouboulis CC, Benhadou F, Byrd A et al (2020) What causes hidradenitis suppurativa? 15 years after. Exp Dermatol 29:1154–1170

    Article  PubMed  Google Scholar 

  67. Zouboulis CC, Frew JW, Giamarellos-Bourboulis EJ et al (2021) Target molecules for future hidradenitis suppurativa treatment. Exp Dermatol 30(suppl 1):8–17

    Article  CAS  PubMed  Google Scholar 

  68. Zouboulis CC, Nogueira da Costa A (2021) Drug repurposing through drug-gene interaction profiles for hidradenitis suppurativa/acne inversa treatment. J Eur Acad Dermatol Venereol 35:e251–e254

    CAS  PubMed  Google Scholar 

  69. Zouboulis CC, Nogueira da Costa A, Fimmel A, Zouboulis KC (2020) Apocrine glands are bystanders in hidradenitis suppurativa and their involvement is gender-specific. J Eur Acad Dermatol Venereol 34:1555–1563

    Article  CAS  PubMed  Google Scholar 

  70. Zouboulis CC, Nogueira da Costa A, Makrantonaki E et al (2020) Alterations in innate immunity and epithelial cell differentiation are the molecular pillars of hidradenitis suppurativa. J Eur Acad Dermatol Venereol 34:846–861

    Article  CAS  PubMed  Google Scholar 

  71. Zouboulis CC, Okun MM, Prens EP et al (2019) Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3‑year results of a phase 3 open-label extention study. J Am Acad Dermatol 80:60–69

    Article  CAS  PubMed  Google Scholar 

  72. Zouboulis CC, Readhead B, Dudley JT (2021) An additional drug repurposing study for hidradenitis suppurativa/acne inversa. Br J Dermatol 184:748–750

    Article  CAS  PubMed  Google Scholar 

  73. Zouboulis CC, Tzellos T, Kyrgidis A et al (2017) Development and validation of IHS4, a novel dynamic scoring system to assess hidradenitis suppurativa/acne inversa severity. Br J Dermatol 177:1401–1409

    Article  CAS  PubMed  Google Scholar 

Download references

Danksagung

Die Hochschulklinik für Dermatologie, Venerologie und Allergologie, Immunologisches Zentrum des Städtischen Klinikums Dessau ist Gesundheitsdienstleister des Europäischen Referenznetzwerkes für seltene und komplexe Hautkrankheiten (ERN Skin – ALLOCATE Skin group).

Author information

Authors and Affiliations

  1. Hidradenitis Suppurativa Foundation e. V., Dessau, Deutschland

    M. von Laffert &  C. C. Zouboulis

  2. Institut für Pathologie, Campus Charité Mitte, Charité-Universitätsmedizin Berlin, Berlin, Deutschland

    M. von Laffert

  3. Universitätsklinik für Dermatologie, Inselspital – Universitätsspital Bern, Bern, Schweiz

    R. E. Hunger

  4. Klinik für Dermatologie, Universitätsspital Basel, Basel, Schweiz

    A. A. Navarini

  5. Hochschulklinik für Dermatologie, Venerologie und Allergologie, Immunologisches Zentrum, Städtisches Klinikum Dessau, Medizinische Hochschule Brandenburg Theodor Fontane und Fakultät für Gesundheitswissenschaften Brandenburg, Auenweg 38, 06847, Dessau, Deutschland

    C. C. Zouboulis

Authors
  1. M. von Laffert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. E. Hunger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. A. Navarini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. C. Zouboulis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. C. Zouboulis.

Ethics declarations

Interessenkonflikt

M. von Laffert und R.E. Hunger geben an, dass kein Interessenkonflikt besteht. A.A. Navarini erhielt Beratungshonorare für seinen Arbeitgeber und/oder war Prüfarzt und/oder war medizinischer Autor und/oder erhielt Grant-Unterstützung von AbbVie, Almirall, Amgen, Biomed, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, GSK, LEO Pharma, Janssen-Cilag, MSD, Novartis, Pfizer, Pierre Fabre Pharma, Regeneron, Sandoz, Sanofi, UCB Pharma. C.C. Zouboulis hat Berater- und Vortragshonorare von Idorsia, Incyte, InflaRx, Janssen, Novartis, Regeneron und UCB erhalten, die nicht mit diesem Manuskript in Verbindung stehen. Seine Abteilung erhielt Honorare von AbbVie, InflaRx, Novartis und UCB für seine Teilnahme an klinischen Studien.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

figure qr

QR-Code scannen & Beitrag online lesen

Die originale Onlineversion dieses Artikels wurde geändert: In diesem Leitthemenbeitrag war die Affiliation des Autors R.E. Hunger leider fehlerhaft und wurde korrigiert. Wir bitten um Beachtung.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

von Laffert, M., Hunger, R.E., Navarini, A.A. et al. Klinische, pathologische und molekulare Biomarker der Hidradenitis suppurativa/Acne inversa. Hautarzt 72, 666–675 (2021). https://doi.org/10.1007/s00105-021-04848-8

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-021-04848-8

Schlüsselwörter

Keywords

Search

Navigation